drugset
drugset / Trial / NCT04972422

A Phase 1b Study of ZN-c3 in Chinese Subjects

NCT04972422 ↗

Phase 1 Unknown 38 enrolled Zentera Therapeutics HK Limited
NaSequentialOpen-labelTreatment

Summary

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics of ZN c3.

Timeline

Start
2021-07-15
Primary completion
2022-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azenosertib Small molecule — —

Indications

cancer